This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.
Voluntarily sign the informed consent and follow the requirements of the protocol.
No gender limit.
Age: ≥18 years old and ≤75 years old.
expected survival time ≥3 months.
Must have at least one measurable lesion according to RECIST v1.1 definition.
ECOG score 0 or 1.
Toxicity of previous antineoplastic therapy has returned to grade 1 or less as defined by NCI-CTCAE v5.0 .
No severe cardiac dysfunction, left ventricular ejection fraction ≥50%.